What We Do in Alzheimer’s

Promise Through Drugs
The ADDF is committed to investing in a diverse portfolio of research programs and strengthening our network of partnerships until we discover a cure.

The ADDF focuses its funding entirely on preclinical research and early-stage clinical trials involving new drug targets that hold great promise but may not be far enough along in the drug development pipeline to receive financial support from the pharmaceutical industry or other partners. The ADDF bridges this critical gap in funding between basic research and drug development, enabling the scientific pursuit of many innovative and novel therapies that might otherwise go unexplored.

Our Funding Model – Venture Philanthropy
The ADDF is a biomedical venture philanthropy. Many of our grants are structured as investments, providing a return that is reinvested in new drug research. From more than $14 million invested in biotechnology programs, $2.8 million has been returned to date and immediately reinvested in new drug research programs. Subsequent to the ADDF’s initial funding, our grantees have received commitments of over $2 billion in follow-on funding from government, pharmaceutical companies and venture capital firms to further advance their drug research.

In 2012, the US Food and Drug Administration (FDA) approved Amyvid™, the first diagnostic test for Alzheimer’s disease. The ADDF seed-funded the research for Amyvid™ from 2000-2004. This successful technology is an important proof-of-concept for the ADDF model, showcasing how early financial support for high-risk projects can lead to and accelerate the development of innovative drugs and diagnostics in Alzheimer’s.

There has never been a greater need for the ADDF. By advancing the most promising research in Alzheimer’s, we have the potential to impact millions of lives around the world.